ID   ACC-MESO-4
AC   CVCL_5114
SY   ACC-Meso-4; MESO-4
DR   CLO; CLO_0050083
DR   BioSample; SAMN03471959
DR   cancercelllines; CVCL_5114
DR   Cosmic; 877274
DR   Cosmic; 1481541
DR   Cosmic; 2759003
DR   Cosmic; 2759232
DR   FANTOM5_SSTAR; 10494-107B8
DR   GEO; GSM551968
DR   GEO; GSM850297
DR   IARC_TP53; 24549
DR   Progenetix; CVCL_5114
DR   RCB; RCB2293
DR   Wikidata; Q54608246
RX   PubMed=16630136;
RX   PubMed=17270034;
RX   PubMed=21245096;
RX   PubMed=25902174;
RX   PubMed=26011428;
RX   PubMed=28553954;
CC   Population: Japanese.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).
CC   Sequence variation: Mutation; HGNC; HGNC:950; BAP1; Simple; p.Tyr724Ter (c.2172delC); Zygosity=Unspecified (PubMed=26011428).
CC   Sequence variation: Mutation; HGNC; HGNC:20796; RASSF6; Simple; p.Arg155fs (c.464_465insA); Zygosity=Unspecified (PubMed=25902174).
CC   Transformant: ChEBI; CHEBI_46661; Asbestos.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Lung, pleura; UBERON=UBERON_0000977.
ST   Source(s): RCB=RCB2293
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 9,10
ST   D5S818: 9,11
ST   D7S820: 12,14
ST   TH01: 7,8
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 23
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x; PMCID=PMC11158456;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x; PMCID=PMC11158069;
RA   Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K.,
RA   Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M.,
RA   Sekido Y.;
RT   "Genomic profiling of malignant pleural mesothelioma with array-based
RT   comparative genomic hybridization shows frequent non-random
RT   chromosomal alteration regions including JUN amplification on 1p32.";
RL   Cancer Sci. 98:438-446(2007).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698; PMCID=PMC4556387;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//